The anticoagulants market is expected to grow to $66.32 billion in 2027 at a CAGR of 10.3%. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The global anticoagulants market grew from $40.63 billion in 2022 to $44.81 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. New York, Ma(GLOBE NEWSWIRE) - announces the release of the report "Anticoagulants Global Market Report 2023". The optimal dosage of andexanet alfa for patients taking other factor Xa inhibitors has not been established.Major players in the anticoagulants market are GlaxoSmithKline plc., Pfizer Inc., Sanofi, Mylan, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo, Alexion Pharmaceuticals Inc., Otsuka, Leo Pharma, Eisai Co. If the dose and/or timing since the last dose of the factor Xa inhibitor is unknown, the high-dose regimen should be used. Patients taking >10 mg of rivaroxaban or >5 mg of apixaban per dose should receive the high-dose regimen, an 800-mg IV bolus dose of andexanet alfa, followed by an 8 mg/minute continuous infusion for up to 120 minutes if their last dose was <8 hours before starting andexanet alfa if the last dose was ≥8 hours before starting andexanet alfa, the low-dose regimen should be used. Patients taking ≤10 mg of rivaroxaban or ≤5 mg of apixaban per dose should receive the low-dose regimen, a 400-mg IV bolus dose of andexanet alfa, followed by a 4 mg/minute continuous infusion for up to 120 minutes. The recommended Andexxa dosage is based on the factor Xa inhibitor taken, its dose, and the time since the last factor Xa inhibitor dose.